Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Opinions Blurb

H1 REVIEW: NIGERIAN PHARMACEUTICAL INDUSTRY, HIGH ON DEBTS LOW ON MARGINS

Nairametrics by Nairametrics
September 5, 2012
in Blurb, Spotlight
Share on FacebookShare on TwitterShare on Linkedin

As an Investor looking to diversify portfolio in the vastly shallow Nigerian Stock Exchange, the pharmaceutical industry is one that an outsider will look to investing in. After all a diversified portfolio like they say helps reduce risk. But how good are the Pharmaceutical companies currently quoted on the stock exchange? Well, the answer emphatically is a resounding bad. The industry as it stands is currently suffering from low margins due to high operating costs, high debt and intense competition from small time importers and counterfeiters. This is no small diagnosis and one which urgently requires a medicine.

A look at the half year unaudited accounts that has recently been released by GSK, Fidson, May and Baker, Pharma-Deko present a sorry state of affairs in the sector. All the companies made a combined turnover of N19b a 26% from the N15.5b posted within the same period last year. Whilst this is a significantly marked improvement it is not pleasant to note that GSK, contributed over 63% of the revenue posted in the first half of 2012 alone. The industry is also bugged down by huge operational cost with margin ranging from 8.6% to just under 15%. It does seem the industry is used to margins under 15% an indication of a highly competitive industry and one in need of massive help from the government in terms of tighter border controls and product standardization. Today drugs and pharmaceutical products of all shapes and sizes find their way into the Nigerian market despite the lofty efforts of regulators like Nafdac.

RelatedPosts

5 important things to consider before buying a stock

The best place to invest N500,000 right now

The sector is also riddled with debts as it struggles to fund new investments and marketing cost necessary to wade of competition. Without GSK (which presently has no debt), the companies all have a combined debt to equity of nearly 1.1:1 with debt taking up 51% of capital structure. This anomaly in capital structure ensures the little operational profits made are utilized to pay for cost of debt leaving little or nothing for equity holders. No wonder profit margins are dismal and return on equity anything but impressive for a sector badly in need of a show off. GSK ,the spark in a pitch of darkness, probably will continue to attract investors money in the years to come despite their modest returns. ROE may have increased year on year from 18% to 21% but operational profit margin dropped from 16% to 14% a sign that efficiency is on a slide.

But GSK can’t be the benchmark for the survival of the sector. The company is tightly run under the influence of its parent company abroad and can leverage on the economies of scale that provides to belly up on revenue and profits. For the others though, a total restructuring is badly needed. Pharmadeko needs new equity and possibly a better business model to be able to survive the next 12 months. May & Baker and Fidson need major cost cutting initiatives to improve its efficiency. Debt may not be an immediate problem for the pair but efficiency if not improved upon drastically will surely drag them into fault lines. The ink may be black for the quartet but as a force the sector is mostly in red.

News continues after this ad


 

 

News continues after this ad


Related

Tags: ANALYSISCOMPANY RESULTSEARNINGS REPORTRESULTSSTOCKS

Comments 2

  1. resourcedat says:
    September 5, 2012 at 4:54 pm

    H1 REVIEW: NIGERIAN PHARMACEUTICAL INDUSTRY, HIGH ON DEBTS LOW ON MARGINS http://t.co/7TQpRjgw

    Reply
  2. ugodre says:
    September 5, 2012 at 4:54 pm

    H1 REVIEW: NIGERIAN PHARMACEUTICAL INDUSTRY, HIGH ON DEBTS LOW ON MARGINS http://t.co/cJKW0Y32

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

inq
avatrade
Stanbic bank
Mega Millions
UBN
Hot forex
Access Bank
Bankers Committee
First bank






    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Brain drain, tax and other economic effects of migration in Nigeria
    • Meet Kenya’s new President-elect- William Samoei Arap Ruto
    • Buhari congratulates William Ruto, Kenya’s president-elect, says both nations are partners in fight against terrorism

    Follow us on social media:

    Recent News

    Fake labs, travel frustrations, passengers allege COVID-19 test Scams at airport, Aviation, Nigerians hit with over 60% delayed and cancelled domestic flights in 2018

    Brain drain, tax and other economic effects of migration in Nigeria

    August 16, 2022
    Meet Kenya’s new President-elect- William Samoei Arap Ruto

    Meet Kenya’s new President-elect- William Samoei Arap Ruto

    August 16, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com